The issue of induction chemotherapy (ICT) interest in locoregionally advanced squamous cell cancer of the head and neck is a real epic that has been carried out over four phase III studies: PARADIGM, DECIDE, NCT01086826 and lastly the conclusive GORTEC 2007-02. With no significant benefit in overall survival of ICT, followed by concurrent chemoradiation over the standard chemoradiotherapy alone, in three of these studies, and a significant number of treatment-related deaths with the standard regimen docetaxel, cisplatin, and fluorouracil, ICT is no longer a hot topic. However, this strategy might still be useful in the aim of limiting the metastatic extension affecting up to 30% of patients: ICT is systematically associated with a reduced metastatic relapse even though the survival effect is never statistically significant when compared directly with concomitant radiochemotherapy. This review summarizes the major studies with their limits and discusses how the ICT could improve the patients' prognosis in the future. Correspondence to Mickaël Burgy, MD, Medical Oncology Department, Centre Paul Strauss, 3 Rue de la Porte de l'Hôpital, 67000 Strasbourg, France Tel: +33 676 204 837; fax: +33 038 825 2448; e-mail: mikebrg@msn.com Received November 21, 2017 Accepted December 27, 2017 Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.
http://ift.tt/2nTX0af
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου